38 - Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS)

Journal article

Peer reviewed

E.M. Stein, A.T. Fathi, C.D. DiNardo, D.A. Pollyea, R.T. Swords, G.J. Roboz, R. Collins, M.A. Sekeres, R.M. Stone, E.C. Attar, …

Leukemia research, Vol.55, pp.S24-S25

2017-04

Metrics

1 Record Views

This output has contributed to the advancement of the following goals:

Source: InCites

Title: 38 - Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS)
Creators: E.M. Stein
A.T. Fathi
C.D. DiNardo
D.A. Pollyea
R.T. Swords
G.J. Roboz
R. Collins
M.A. Sekeres
R.M. Stone
E.C. Attar
A. Tosolini
Q. Xu
M. Amatangelo
I. Gupta
R.D. Knight
S. de Botton
M.S. Tallman
H.M. Kantarjian
Publication Details: Leukemia research, Vol.55, pp.S24-S25
Publisher: Elsevier Ltd
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031757321402976